Free accessResearch articleFirst published online 1995-6
Synergistic Inhibition of Human Immunodeficiency Virus Type 1 in vitro by 6-0-butanoylcastanospermine (MDL 28574) in Combination with Inhibitors of the Virus-Encoded Reverse Transcriptase and Proteinase
The anti-human immunodeficiency virus type 1 (HIV-1) activity of the α-glucosidase 1 inhibitor 6-0-butanoylcastanospermine (MDL 28574) was assessed in combination with the 2′,3′-dideoxynucleoside analogues zidovudine (AZT), didanosine (ddl) and zalcitabine (ddC). MDL 28574 was also evaluated in combination with the non-nucleoside reverse transcriptase (RT) inhibitor nevirapine and the HIV proteinase inhibitor saquinavir (Ro-31-8959). Drug interactions were examined by the isobologram technique and by calculating combination indices (C.l.s). In all cases synergistic inhibition of HIV-1 replication was observed. In three-drug combinations, a marked synergistic antiviral effect was also observed, with C.I. values in the range 0.35-0.44 for MDL 28574 in combination with AZT and nevirapine, and in the range 0.34-0.67 for MDL 28574 in combination with AZT and saquinavir. Moreover, the combination of MDL 28574 with other drugs did not produce detrimental effects on cell division. MDL 28574 is currently in clinical trials and may have an important role in combination chemotherapy for HIV infections.
BerenbaumM.C. (1989) What is synergy?Pharmacol Rev41: 93–141.
2.
BrennanT.M.TaylorD.L.BridgesC.G.LeydaJ.P., and TymsA.S. (1995) The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC442, alone and in combination with other anti-HIV compounds. Antiviral Res, in press.
3.
ChowY-K.HirschM.S.MerrillD.P.BechtelL.J.EronJ.J.KaplanJ.C., and D'AquilaT. (1993) Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature361: 650–653.
4.
DornsifeR.E.St ClairM.H.HuangAT.PanellaT.J.KoszalkaG.W.BurnsC.L., and AverettD.R. (1991) Anti-human immunodeficiency virus synergism by zidovudine (3′-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob Agents Chemother35: 322–328.
5.
EminiE.A.GrahamD.J.GotlibL.CondraJ.H.ByrnesV.W., and SchleifW.A. (1993) HIV and multidrug resistance. Nature364: 679.
6.
FellowsL.E. (1986) The biological activity of polyhydroxyalkaloids from plants. Pesticide Sci17: 602–606.
7.
FischlM.A.ResnickL.CoombsR.KremerA.B.PottageJ.C.FassR.J.FifeK.H.PowderlyW.G.CollierA.C.AspinallR.L.SmithS.L.KowalskiK.G., and WallemarkC.-B. (1994) The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334), and zidovudine in patients with HIV-1 infection and 200-500 CD4cells/mm3. J AIDS7: 139–147.
8.
FleetG.W.J.KarpasA.DwekR.A.FellowsL.E.TymsA.S.PeturssonS.NamgoongS.K.RamsdenN.G.SmithP.W.SonJ.C.WilsonF.WittyD.R.JacobG.S., and RademacherT.W. (1988) Inhibition of HIV replication by amino-sugar derivatives. FEBS Lett237: 128–132.
9.
FuhrmannU.BauseE., and PloeghH. (1985) Inhibitors of oligosaccharide processing. Biochim Biophys Acta825: 5–110.
10.
GrutersR.A.NeefjesJ.J.TersmetteM.de GoedeR.E.Y.TulpA.HuismanH.G.MiedemaF., and PloeghH.L. (1987) Interference with HIV-induced syncytium formation and virus infectivity by inhibitors of trimming glucosidase. Nature330: 74–77.
11.
HartshornK.L.SandstromE.G.NeumeyerD.ParadisT.J.ChouT-C.SchooleyR.T., and HirschM.S. (1986) Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon. Antimicrob Agents Chemother30: 189–191.
12.
JohnsonV.A.WalkerB.D.BarlowM.A.ParadisT.J.ChouT.-C., and HirschM.S. (1989a) Synergistic inhibition of human immunodeficiency virus type 1 and type 2 replication in vitro by castanospermine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother33: 53–57.
13.
JohnsonV.A.BarlowM. A.ChouT.-C.FisherR.A.WalkerB.D.HirschM.S., and SchooleyR.T. (1989b) Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by recombinant soluble CD4 and 3′-azido-3′-deoxythymidine. J Infect Diseases159: 837–844.
14.
JohnsonV.A.BarlowM.A.MerrillD.P.ChouT.-C., and HirschM.S. (1990) Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. J Infect Diseases161: 1059–1065.
15.
KarpasA.FleetG.W.J.DwekR.A.PeturssonS.NamgoongS.K.RamsdenN.G.JacobG.S., and RademacherT.W. (1988) Aminosugar derivatives as potential anti-human immunodeficiency virus agents. Proc Natl Acad Sci USA85: 9229–9233.
16.
KoupR.A.BrewsterF.GrabP., and SullivanJ.L. (1993) Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesin. AIDS7: 1181–1184.
17.
LarderB.A.DarbyG., and RichmanD.D. (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science243: 1731–1734.
18.
LarderB.A.KellamP., and KempS.D. (1993) Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature365: 451–453.
19.
LiuP.S.HoekstraW.J., and KingC.H.R. (1990) Synthesis of potent anti-HIV agents: esters of castanospermine. Tetrahedron Lett31: 2829.
20.
McDowellW., and SchwarzR.T. (1988) Dissecting glycoprotein biosynthesis by the use of specific inhibitors. Biochimie70: 1535–1549.
21.
MerluzziV.J.HargraveK.D.LabadiaM.GrozingerK.SkoogM.WuJ.C.ShihC-K.EcknerK.HattoxS.AdamsJ.RosenthalA.S.FaanesR.EcknerR.J.KoupR.A., and SullivanJ.L. (1990) Inhibition of HIV replication by a non nucleoside reverse transcriptase inhibitor. Science250: 1411–1413.
22.
NashR.J.FellowsL.E.DringJ.V.FleetG.W.J.GirdharA.RamsdenN.G.PeachJ.M.HegartyM.P., and ScofieldA.M. (1990) Two alexines [3-hydroxymethyl-1,2,7-trihydroxypyrrolizidines] from Castanospermum australe. Phytochemistry29: 1356–1358.
23.
PanX-Z.QiuZ-D.BaronP.A.GoldJ.W.M.PolskyB.ChouT-C., and ArmstrongD. (1992) Three-drug synergistic inhibition of HIV-1 replication in vitro by 3′-fluoro-3′-deoxythymidine, recombinant soluble CD4, and recombinant interferon-alpha. AIDS Res Hum Retro8: 589–595.
24.
PauwelsR.BalzariniJ.ScholsD.BabaM.DesmyterJ.RosenbergI.HolyA., and De ClercqE. (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Met20: 309–321.
25.
RatnerL. (1992) Glucosidase inhibitors for the treatment of HIV infection. AIDS Res Hum Retro8: 165–173.
26.
RatnerL., and vander HeydenN. (1993) Mechanism of action of N-butyl Deoxynojirimycin in inhibiting HIV-1 infection and activity in combination with nucleoside analogs. AIDS Res Hum Retro9: 291–297.
27.
RichmanD.D. (1992) HIV drug resistance. AIDS Res Hum Retro8: 1065–1073.
28.
RobertsN.A.MartinJ.A.KinchingtonD.BroadhurstA.V.CraigC.DuncanI.B.GalpinS.A.HandaB.K.KayJ.KrohnA.LambertR.W.MerrettJ.H.MillsJ.S.ParkesK.E.B.RedshawS.RitchieA.J.TaylorD.L.ThomasG.J., and MachinP.J. (1990) Rational design of peptide-based HIV proteinase inhibitors. Science248: 358–361.
29.
SaagM.S.EminiE.A.LaskinO.L.DouglasJ.LapidusW.I.SchleifW.A.WhitleyR.J.HildebrandC.ByrnesV.W.KappesJ.C.AndersonK.W.MassariF.E.Shaw, G.M., and The L-697,661 Working Group. (1993) A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N Engl J Med329: 1065–1072.
30.
SarverN.BlackR.J.BridgesS., and ChriseyL. (1992) Frontiers in HIV-1 therapy: Fourth conference of the NIAID National Cooperative Drug Discovery Groups - HIV. AIDS Res Hum Retro8: 659–667.
31.
St ClairM.H.MartinJ.L.Tudor-WilliamsG.BachM.C.VavroC.L.KingD.M.KellamP.KempS.D., and LarderB.A. (1991) Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science253: 1557–1559.
32.
ShimizuH.TsuchieH.YoshidaK.MorikawaS.TsuruokaT.YamamotoH.UshijimaH., and KitamuraT. (1990) Inhibitory effect of novel 1-deoxynojirimycin derivatives on HIV-1 replication. AIDS4: 975–979.
33.
SuhnelJ. (1990) Evaluation of synergism or antagonism for the combined action of antiviral agents. Antiviral Res13: 23–40.
34.
SunkaraP.S.TaylorD.L.KangM.S.BowlinT.L.LiuP.S.TymsA.S., and SjoerdsmaA. (1989) Anti-HIV activity of castanospermine analogues. LancetI: 1206.
35.
TaylorD.L.SunkaraP.S.LiuP.S.KangM.S.BowlinT.L., and TymsA.S. (1991) 6-0-Butanoylcastanospermine (MDL 28574) inhibits glycoprotein processing and the growth of HIVs. AIDS5: 693–698.
36.
TaylorD.L.BridgesC.G.KangM.S.BrennanT.M.SunkaraP., and TymsA.S. (1994) Inhibition of α-glucosidase 1 of the glycoprotein processing enzymes by 6-0-butanoylcastanospermine (MDL 28574) and its consequences in HIV infected T-cells. Antimicrob Agents Chemother38: 1780–1787.
37.
TymsA.S.BerrieE.M.RyderT.A.NashR.J.HegartyM.P.TaylorD.L.MobberleyM.A.DavisJ.M.BellE.A.JeffriesD.J.Taylor-RobinsonD., and FellowsL.E. (1987) Castanospermine and other plant alkaloids inhibitors of glucosidase activity block the growth of HIV. LancetII: 1025–1026.
38.
van DorsselaerV.SchirlinD.TarnusC.TaylorD.L.TymsA.S.WeberF.BaltzerS.RemyJ.M.BrennanT., and JanowickD (1994) Increased antiviral activity of HIV protease inhibitors of the difluorostatone type bearing (R)-valinol derivatives as novel C-termini. Bioorg Med Chem Lett4: 1213–1218.
39.
WalkerB.D.KowalskiM.GohW.C.KozarskyK.KriegerM.RosenC.RohrschneiderL.HaseltineW.A., and SodroskiJ. (1987) Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. Proc Natl Acad Sci USA84: 8120–8124.
